Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for Aggressive Diffuse Large B-Cell Lymphoma
Validation of Progression of Disease in 24 months(POD24 )as a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials
Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)
Four versus Two Years of Rituximab Maintenance following Bendamustine-Rituximab in pts with Previously Untreated Follicular Lymphoma:Results of the prospective, randomized multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN trial)
Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy..
Acute Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Adults
The Presence of Pleural Effusion at Diagnosis Predicts Poor Outcomes in Diffuse Large B-Cell Lymphoma Patients with MYC-Rearrangement or Double Protein Expression
Randomized phase II study of R-CHOP-14 versus R-CHOP-14 followed by CHASER as induction therapy for high-dose chemotherapy (HDT), LEED, and autologous stem-cell transplantation (ASCT) in poor-risk diffuse large B-cell lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)
Evaluation of Tumor Burden for Predicting Survival in Patients with Follicular Lymphoma Receiving First-Line R-CHOP Treatment: Comparison of Different Definition of GELF Criteria